About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04359004

A Study to Evaluate the Effect of Vagus Nerve Stimulation in Patients Undergoing VT Ablation

Vagus nerve stimulation (VNS) has been shown to be beneficial in multiple studies including heart failure. The goal of this clinical investigation is to gain additional information about how vagus ner...

Lead sponsor: University of California, Los Angeles•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of California, Los Angeles

Collaborators

National Institutes of Health (NIH)

This study is a non-randomized, prospective study in 6 patients with scar mediated ventricular arrhythmias who are scheduled to undergo a catheter ablation procedure. The study will last up to 30 minutes in the cardiac electrophysiology lab. Cervical VNS is performed percutaneously through the internal jugular vein during the patient's routine ventricular tachycardia (VT) ablation procedure.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Presence of structural heart disease as defined as EF ≤ 50% or presence of ventricular scar as detected by imaging modalities or electroanatomic mapping, hypertrophic cardiomyopathy, cardiac sarcoidosis, or arrhythmogenic right ventricular cardiomyopathy.
•Age \> 18 years old
•Underlying sinus rhythm with heart rate \> 50 bpm.
•Provision of signed/dated informed consent and stated willingness to comply with all study procedures

Exclusion Criteria

•Active ongoing cardiac ischemia as assessed by: ECG, cardiac enzymes, symptoms, coronary angiography with evidence of significant epicardial coronary stenosis (\>70%), or stress testing. (Note: positive troponin assay due to Internal Cardiac Defibrillator (ICD) shocks is not an exclusion criterion).
•Status post orthotopic heart transplantation
•Women who are pregnant (as evidenced by pregnancy test if pre-menopausal).
•Unable or unwilling to comply with protocol requirements.
•Known channelopathy such as long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic VT.
•Known peripheral neuropathy or history of autonomic dysfunction due to non-cardiac causes.
•New York Heart Association Class IV heart failure or use of current vasopressor medications
•Incessant VT
•Persistent atrial fibrillation
•Frequent premature atrial or ventricular contractions
•Inability to give informed consent.

Related studies

Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)

NCT06703489 · Ventricular Tachycardia (VT)

NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

NCT07018596 · Atrial Fibrillation Paroxysmal, Cardiac Ablation, and more

CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation

NCT06696170 · Atrial Fibrillation Paroxysmal, Cardiac Ablation, and more

Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation

NCT07201506 · Ablation of Arrhythmias, Premature Ventricular Contractions, and more

StereoTactic Ablative RadioTherapy of Cardiac Arrhythmias

NCT04843683 · Cardiac Arrhythmia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 13, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment5

Start dateDec 2020

Last updatedNov 13, 2023

Condition

Arrhythmia Ventricular Tachycardia (VT)

Locations shown

UCLA Health

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions